195 related articles for article (PubMed ID: 10851069)
1. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins.
Lou J; Cao W; Bernardin F; Ayyanathan K; RauscherIII FJ; Friedman AD
Oncogene; 2000 May; 19(22):2695-703. PubMed ID: 10851069
[TBL] [Abstract][Full Text] [Related]
2. AML1 stimulates G1 to S progression via its transactivation domain.
Bernardin F; Friedman AD
Oncogene; 2002 May; 21(20):3247-52. PubMed ID: 12082641
[TBL] [Abstract][Full Text] [Related]
3. CBFbeta-SMMHC slows proliferation of primary murine and human myeloid progenitors.
D'Costa J; Chaudhuri S; Civin CI; Friedman AD
Leukemia; 2005 Jun; 19(6):921-9. PubMed ID: 15815715
[TBL] [Abstract][Full Text] [Related]
4. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
5. CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells.
Cao W; Britos-Bray M; Claxton DF; Kelley CA; Speck NA; Liu PP; Friedman AD
Oncogene; 1997 Sep; 15(11):1315-27. PubMed ID: 9315100
[TBL] [Abstract][Full Text] [Related]
6. Acceleration of G(1) cooperates with core binding factor beta-smooth muscle myosin heavy chain to induce acute leukemia in mice.
Yang Y; Wang W; Cleaves R; Zahurak M; Cheng L; Civin CI; Friedman AD
Cancer Res; 2002 Apr; 62(8):2232-5. PubMed ID: 11956074
[TBL] [Abstract][Full Text] [Related]
7. AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression.
Bernardin-Fried F; Kummalue T; Leijen S; Collector MI; Ravid K; Friedman AD
J Biol Chem; 2004 Apr; 279(15):15678-87. PubMed ID: 14747476
[TBL] [Abstract][Full Text] [Related]
8. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.
Bernardin F; Yang Y; Civin CI; Friedman AD
Cancer Biol Ther; 2002; 1(5):492-6. PubMed ID: 12496475
[TBL] [Abstract][Full Text] [Related]
9. Leukemogenesis by CBF oncoproteins.
Friedman AD
Leukemia; 1999 Dec; 13(12):1932-42. PubMed ID: 10602413
[TBL] [Abstract][Full Text] [Related]
10. Core-binding factor: a central player in hematopoiesis and leukemia.
Speck NA; Stacy T; Wang Q; North T; Gu TL; Miller J; Binder M; Marín-Padilla M
Cancer Res; 1999 Apr; 59(7 Suppl):1789s-1793s. PubMed ID: 10197598
[TBL] [Abstract][Full Text] [Related]
11. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
12. The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation.
Cao W; Adya N; Britos-Bray M; Liu PP; Friedman AD
J Biol Chem; 1998 Nov; 273(47):31534-40. PubMed ID: 9813068
[TBL] [Abstract][Full Text] [Related]
13. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
14. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.
Kummalue T; Lou J; Friedman AD
Mol Cell Biol; 2002 Dec; 22(23):8278-91. PubMed ID: 12417730
[TBL] [Abstract][Full Text] [Related]
15. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.
Greider C; Chattopadhyay A; Parkhurst C; Yang E
Oncogene; 2002 Nov; 21(51):7765-75. PubMed ID: 12420213
[TBL] [Abstract][Full Text] [Related]
16. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I.
Iwanaga R; Ohtani K; Hayashi T; Nakamura M
Oncogene; 2001 Apr; 20(17):2055-67. PubMed ID: 11360190
[TBL] [Abstract][Full Text] [Related]
18. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO.
Lausen J; Liu S; Fliegauf M; Lübbert M; Werner MH
Oncogene; 2006 Mar; 25(9):1349-57. PubMed ID: 16247445
[TBL] [Abstract][Full Text] [Related]
19. DNA-binding domain of AML1, expressed in t(8;21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 32D cl3 myeloid cells.
Britos-Bray M; Sacchi N; Friedman AD
Leukemia; 1996 Jun; 10(6):984-90. PubMed ID: 8667656
[TBL] [Abstract][Full Text] [Related]
20. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]